Navigation Links
Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients
Date:7/30/2014

(PHILADELPHIA) Up to 20 percent of Parkinson's disease (PD) patients and their families may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as compulsive gambling, sexual behavior, eating, or spending. Yet the presence of PD in these patients can severely limit or complicate treatment options. A team of investigators from the Perelman School of Medicine at the University of Pennsylvania and the Parkinson's Disease Research, Education and Clinical Center (PADRECC) at the Philadelphia Veterans Affairs Medical Center conducted a pilot study and found that the opioid antagonist naltrexone may be an effective treatment for diminishing ICD symptoms in PD patients. The results were published in the journal Neurology.

Researchers believe that these issues may arise as a result of medications used to treat the disease, but also could be a result of the disease itself, or a combination of both. ICDs can create financial, personal, employment, and social problems that add to the burden on patients and caregivers whose lives are already devastated by PD.

A sample of 50 PD patients, all of whom began displaying their ICD symptoms after both the onset of PD and the initiation of dopamine agonist treatment (which was continued normally during the course of the study) were placed on a placebo-controlled flexible dose of naltrexone, 50-100 mg/day.

Naltrexone was FDA approved for the treatment of alcohol dependence in 1994. Since then, a number of studies have confirmed its efficacy in reducing frequency and severity of relapse to drinking. It is less commonly used in the treatment of opioid addiction and rapid detoxification.

Patients were assessed by several evaluation measures, chiefly the Clinical Global Impression-Change (CGI-C), which was completed by a clinician, and the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS), developed by the research team and completed by the patient. Several other assessment tools were used to evaluate PD symptoms and other psychological responses.

The outcome of the eight-week study was not definitive, reports lead author Daniel Weintraub, MD, an assistant professor of Psychiatry and a Fellow in Penn's Institute on Aging. "On the primary outcome measure (the CGI-C), we did not see a benefit in terms of the medication," he says. However, on the secondary measure (the QUIP-RS), "we did see a benefit of treatment, suggesting at least on a self-rated measure of ICD severity that naltrexone did help diminish the severity of ICD symptoms in PD patients."

Weintraub explains, "The interesting thing is that ICDs may not be specific to PD at all, but only to the medication which happens to be used primarily in PD patients. It may not be a disease effect as opposed to just excessive dopamine stimulation of a particular type. These PD medications are very potent medications for the D2 subset of dopamine receptors in the brain, and it seems that if you stimulate or overstimulate those, people may develop these problems whether or not they have PD."

Weintraub and his colleagues believe that the small size of the study and the inherent differences in interpreting an outcome measure based on a global rating such as the CGI-C compared to a continuous measure of symptom severity such as the QUIP-RS may limit their results.

Weintraub says this pilot study is a promising first step in identifying ICD treatments for PD patients, and potentially, improving their quality of life. "It shows that it is possible to do a randomized controlled trial for this problem in PD, which is an important point," he notes. "It shows that you have to think carefully about the primary outcome measures. And I think it supports further study of medications like naltrexone and other opioid antagonists with a larger, more definitive clinical trial."


'/>"/>

Contact: Lee-Ann Donegan
leeann.donegan@uphs.upenn.edu
215-349-5660
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
2. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
3. UI researchers: Bracing is effective in adolescents with idiopathic scoliosis
4. Researchers: Biomarkers predict effectiveness of radiation treatments for cancer
5. GW researchers: Acute kidney injury and chronic kidney disease as interconnected syndromes
6. Osteoarthritis risk not diminished in double bundle ACL surgeries
7. Health-care costs hit the elderly hard, diminish financial wellbeing
8. Diminished Taste Buds Noted in Obese Children
9. Condoms Dont Diminish Sexual Pleasure, Study Finds
10. Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale"
11. Learn to Let Go of Fear, Diminish Suffering in Upcoming Teleseminar Hosted by Spiritual Teacher Heather Hans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million ... million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world will ... Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration of ...
(Date:5/26/2016)... , ... May 26, 2016 , ... In an effort to provide hair restoration information ... both Snapchat users and those who do not use the app. Dr. Mohebi, the founder ... page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to ...
(Date:5/26/2016)... ... May 26, 2016 , ... North Cypress Medical ... at Blackhorse Golf Club in Cypress. With the help of community partners, the event ... empowers, and renews hope for wounded service members and their families through health, wellness, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a leading developer ... Instructor Certification Course in Stoughton, Massachusetts. The course was led by Power Systems’ ... 8 hour interactive course to qualify participants as certified PowerWave trainers. , ...
(Date:5/26/2016)... ... ... The introduction of our professional athletes coincides with the company’s new campaign: “LOOK ... are proud to introduce Meghan Klingenberg, defender and World Champion with the US Women’s ... Los Angeles who was a second round selection in the 2012 NFL draft. We ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... -- Open Access Journal Focusing on ... Elsevier , a world-leading provider of scientific, technical ... launch of Clinical Neurophysiology Practice ... clinical practice issues in clinical neurophysiology. The journal will ... and didactic reviews. It is an official journal of ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
Breaking Medicine Technology: